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This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan
(TEGAFIRI) or with oxaliplatin (TEGAFOX). One hundred and forty-three patients with measurable, non-resectable metastatic
colorectal cancer were randomised in a multicentre study to receive TEGAFIRI (UFT 250mgm
 2day days 1–14, LV 90mgday days
1–14, irinotecan 240mgm
 2day 1; q21) or TEGAFOX (UFT 250mgm
 2day days 1–14, LV 90mgday days 1–14, oxaliplatin
120mgm
 2day 1; q21). Among 143 randomised patients, 141 were analysed (68 received TEGAFIRI and 73 TEGAFOX). The main
characteristics of the two arms were well balanced. The most common grade 3–4 treatment-related adverse events were
neutropenia (13% of cases with TEGAFIRI; 1% in the TEGAFOX group). Diarrhoea was prevalent in the TEGAFIRI arm (16%) vs
TEGAFOX (4%). Six complete remission (CR) and 19 partial remission (PR) were recorded in the TEGAFIRI arm (odds ratio (OR):
41.7; 95% confidence limit (CL), 29.1–55.1%), and six CR and 22 PR were recorded in the TEGAFOX group, (OR: 38.9; 95% CL,
27.6–51.1). At a median time follow-up of 17 months (intequartile (IQ) range 12–23), a median survival probability of 20 and 19
months was obtained in the TEGAFIRI and TEGAFOX groups, respectively. Median time to progression was 8 months for both
groups. TEGAFIRI and TEGAFOX are both effective and tolerable first-line therapies in MCRC patients. The employment of UFT/LV
given in doublet combination is interesting and the presented data appear comparable to equivalent infusion regimens described in
the literature. The safety profile of the two combinations also allows an evaluation with other biological agents such as monoclonal
antibodies.
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Up until the mid-1990s, best supportive care was still a valid
treatment option in the treatment of advanced metastatic colo-
rectal cancer and 5-fluorouracil (5-FU) represented the mainstay
chemotherapy. In the last decade, irinotecan (CPT-11), oral
fluoropyrimidines, oxaliplatin (L-OHP) and monoclonal anti-
bodies have been added to the armamentarium of treatment
options. This, of course, presents a challenge. Fluorouracil infusion
in association with CPT-11 or L-OHP has shown a good activity
and tolerability profile in metastatic colorectal cancer; therefore,
FOLFIRI or FOLFOX are now considered the first-line options (de
Gramont et al, 2000; Douillard et al, 2000; Saltz et al, 2000; Mayer,
2004). Many randomised studies have proved the equivalence in
terms of activity or overall survival between FOLFOX and FOLFIRI
regimens with a slight difference in the safety profile. FOLFOX is
characterised by neutropenia (G3-4: 41%), neurotoxicity (G3-4:
18%) and diarrhoea (G3-4: 12%), whereas FOLFIRI by neutropenia
(G3-4: 46%) and diarrhoea (G3-4: 14%) (Goldberg et al, 2004;
Tournigand et al, 2004; Colucci et al, 2005).
Uracil/ftorafur is an oral third-generation fluoropyrimidine and
was synthesised by Hiller in 1967 (Milano et al, 2004). This drug
consists of two main compounds: tegafur, which is a pro-agent of
5-FU, and uracil, which is a simple competitive inhibitor of
dihydropyrimidine dehydrogenase (DPD) activity. After gastro-
intestinal absorption, tegafur is converted to 5-FU by the liver
microsomal system, mainly by the P-450 cytochrome. In colorectal
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scancer patients, the concentrations of 5-FU in serum, tumour and
normal mucosa at various intervals after the final dose of UFT
have been examined (Ho et al, 1998). Whereas the serum 5-FU
concentration decreased to very low levels by 24h following the
UFT dose, the intratumoral 5-FU concentration decresed to only
about half, and drug levels in normal mucosa were maintained at
least 48h after the final dose (Sadahiro et al, 2001). However 5-FU
concentrations in the normal mucosa were approximately one-
third of those measured in tumour tissue. Three phase III studies
have been conducted to compare the efficacy and toxicity of UFT
and bolus 5-FU, both modulated by leucovorin (LV) (Carmichael
et al, 2002; Douillard et al, 2002; Lembersky et al, 2006). The
results documented that they are equivalent in efficacy and that
UFT/LV has a more favourable toxicity profile, with less
neutropenia, diarrhoea, nausea, vomiting and mucositis. Given
the in vitro synergy between L-OHP and UFT in the HT29 cell
xenograft model, and between CPT-11 and 5-FU, some phase I
studies have been conducted to define the recommended dose
(Louvet et al, 2000; Prince and Hill, 2000; Alonso et al, 2001).
Therefore, in the light of the above, it is to be expected that the
combination of UFT/LV with CPT-11 (TEGAFIRI) or L-OHP
(TEGAFOX) will be at least as effective as the corresponding
infusion regimen.
The aims of this multicentre randomised non-comparative
phase II study are to evaluate the safety profile of TEGAFIRI or
TEGAFOX as first-line treatment and to determine the therapeutic
efficacy in terms of response rate, duration of response, time to
progression and overall survival.
MATERIALS AND METHODS
Patient eligibility
Patients with metastatic colorectal cancer, previously untreated by
chemotherapy for advanced disease, were eligible for this study.
Adjuvant chemotherapy, if administered, must have been com-
pleted at least 6 months before enrolment in the study. Histological
confirmation of colorectal adenocarcinoma and the presence of at
least one unidimensionally measurable lesion was requested. The
patients had to be 18–75 years of age, with ECOG performance
status 0–2. Other eligibility criteria were: absolute neutrophil
count X2.0 10
9l
 1 at least; platelets X100 10
9l
 1 or more,
haemoglobin X10gdl
 1; lactic deydrogenase (LDH) p1500Ul
 1;
serum creatinine p1.25mgdl
 1; serum bilirubin p1 upper
normal limit (UNL), alanine aminotransferase (ALAT) or aspartate
aminotransferase (ASAT) or alkaline phosphatase o2.5 UNL.
However, level of up to five times the UNL for alkaline phos-
phates, ALAT and ASAT were allowed in patients with liver
metastases. The study was conducted according to the Good
Clinical Practices and Declaration of Helsinki. Written informed
consent was required. The study and all current amendments
were approved by the Ethics Committees of all of the participating
centres.
Contraceptive measures were required for patients with
reproductive potential; patients were not included if they were
pregnant or lactating, had a history of other cancer except cured
basal cell carcinoma of skin and carcinoma in situ of the uterine
cervix, or if they had not fully recovered from recent, major
surgery (within 4 weeks). Other exclusion criteria were presence of
organ allograft, CNS involvement or neurological or psychiatric
disorders, that could interfere with treatment compliance, severe
cardiac disease or a myocardial infarction within the previous 12
months, uncontrolled metabolic disorders or active serious
infections, inflammatory bowel disease, bowel obstruction or
history of chronic diarrhoea and malabsorption syndrome.
Patients were also excluded from the study if they had active
neuropathy or previous fluoropyrimidines toxicity.
Study design and treatment
This was an open-label, multicentre, randomised non-comparative
Phase II study, conducted by the Italian Trials in Medical Oncology
(ITMO) group and coordinated by Medical Oncology Unit 2.
Patients who fulfilled the selection criteria were stratified by centre
and by previous adjuvant chemotherapy and centrally randomised
by the ITMO Scientific Office. TEGAFIRI consisted of UFT:
250mgm
 2day and LV: 90mgtotaldose daily, given for 14 days,
combined with a 1-h infusion of CPT-11: 240mgm
 2 on day 1.
TEGAFOX was administered as UFT: 250mgm
 2day and LV:
90mgtotaldose
 1 daily, given for 14 days, combined with a 3-h
infusion of L-OHP: 120mgm
 2 on day 1. The total daily UFT
dose was divided to be given every 8h; if the dose could not be
equally divided, the greatest dose was administered in the
morning. The treatment was given for a maximum of six cycles
in presence of disease stabilisation or eight cycles in case of
objective responses, as shown in Figure 1. The therapy was
interrupted for unacceptable toxicity or consent withdrawal.
Safety and efficacy analyses
Safety analyses included all patients who received at least one dose
of the study medication. The analysis also included clinical
assessments of adverse event reactions. Complete blood counts
were obtained before every cycle and 21 days after the last day of
chemotherapy.
The intensity of clinical adverse events was graded according
to the NCI-CTC grading system (version 3.0). Adverse events not
listed on the NCI-CTC grading system were graded as mild
(grade 1), moderate (grade 2), severe (grade3) or life-threatening
(grade 4). Hand–foot syndrome (palmar–plantar erythrody-
sesthesia-HFS) was classified as 3 grades: grade 1 (numbness,
dysesthesia, painless swelling or erythema not disrupting normal
activity); grade 2 (painful erythema with swelling affecting daily
living activities); grade 3 (desquamation, ulceration, blistering or
severe pain or any symptoms leading to an inability to work or
perform daily living activities).
All cases who had received at least three cycles of study
treatment and had at least one tumour assessment were considered
evaluable for activity. Patients who failed to follow-up or who
refused therapy were also included. Basal evaluation was
performed within 28 days before starting treatment. Tumour
dimensions that had a minimum size of at least one diameter of
10mm were assessed using computerised tomography scans and
magnetic resonance imaging. Figure 1 shows the treatment plan
and the planned disease revaluation. All responses were confirmed
and complete remission (CR), partial remission (PR), stable
disease (SD) and progressive disease (PD) were defined according
to the response definitions of the RECIST criteria (Therasse et al,
2000).
Treatment modifications
In individual patients, treatment interruption or dose reduction
was not indicated for reactions unlikely to become serious or life
threatening, or for grade 1 toxicity. Treatment was interrupted in
cases of grade 2 toxicity or worse, and it was resumed once the
adverse event resolved or improved to grade 0 or 1.
For patients experiencing grade 3–4 neutropenia and/or
thrombocytopenia, and/or febrile neutropenia, at the moment of
recycle, the treatment was delayed for 1–2 weeks to allow for
recovery, and then the dose reduced by 25% of the all study drugs.
For patients who experienced a second occurrence of grade 3–4
toxicity, a further reduction by 50% was permitted. Treatment was
definitely discontinued in cases of new occurrence of grade 3–4
toxicity.
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sIn the presence of grade 2–4 diarrhoea, the UFT/LV adminis-
tration was interrupted until recovery. The drug was then restarted
with a reduction in dose by 25% in presence of grade 3–4 toxicity
or with the second appearance of grade 2 diarrhoea. If grade X2
HFS and/or mucositis occurred, the UFT administration was
immediately stopped.
To ensure that the patient has been complying adequately with
their medication regimen, at each visit the returned medication
was checked and counted and the amount returned recorded in the
drug dispensing log. If the patient stopped treatment, for any other
reason other than side effects, for more than 1 week, he or she was
withdrawn from the trial for non-compliance.
Statistical analysis
The objective of the study was to evaluate separetely in each of the
two study arms the safety and efficacy profiles of the two regimens
in terms of the onset of grade 3–4 side effects (at least two
sequential episodes of grade 3 or one episode of grade 4
neutropenia or diarrhoea) and the response rate (RR). The
response rate was estimated as the fraction of evaluable patients
who showed CR or PR; the corresponding 95% confidence limits
were obtained by means of exact binomial calculation. The toxicity
rate and corresponding confidence limits were calculated in the
same manner. A sample of 60 subjects in each study arm had been
planned following the Bayesian approach proposed by Thall et al
(1995). This approach allowed early trial discontinuation in case of
either insufficient antitumour activity or excessive treatment
toxicity and was checked by simulation assuming an increase in
the toxicity rate above 40% and/or a reduction of the response rate
below 35%.
RESULTS
Between July 2002 and November 2004, 143 patients were
randomised by 14 Italian Institutions. Two patients were not
analysed because they were never treated (rapidly progressive
disease and ineligibility criteria); 68 patients were assigned to
TEGAFIRI and 73 to TEGAFOX. Table 1 shows the main
demographic and baseline characteristics that were comparable
between treatment arms. Most patients had received no prior
adjuvant therapy. Synchronous metastasis were documented in
72% of TEGAFIRI and in 67% of TEGAFOX cases. Twenty-one
(31%) patients assigned to TEGAFIRI and 32 (44%) assigned to
TEGAFOX had the liver as the only metastatic site. Baseline LDH
values were elevated mostly in TEGAFIRI patients. However,
elevations over 1.500U l
 1 were not allowed by protocol criteria.
CEA value was elevated in 56% of TEGAFIRI and in 53% of the
TEGAFOX group.
Safety analysis
All 141 patients who received at least one cycle of study medication
were evaluable for safety. A total of 362 TEGAFIRI cycles and 411
TEGAFOX cycles were administered, with a median of six courses
1st–2nd–3rd– Cycles
Restaging
Disease progression Stable disease Objective response
4th Cycle Second line therapy follop-up
Restaging Restaging
Stable disease Objective response
5th–6th–7th Cycles
Restaging
8th Cycle
7th Cycle
Follow-up every
3 months
Follow-up every
3 months
4th–5th–6th Cycles
Figure 1 Study design.
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sper patient (range 1–8) in both arms. Treatment was discontinued
owing to toxicity in 11 TEGAFIRI (nine for gastrointestinal
syndrome, and two for haematological side effects) and four
TEGAFOX patients (three for allergic reaction and one for
haematological side effect). One 60-day death was recorded in
the TEGAFIRI arm, and no deaths were recorded in the TEGAFOX
arm. Regarding dose reduction, TEGAFIRI cycles were adminis-
tered with only a UFT reduction in 44 cycles (12%) and with a
CPT-11 reduction in 11 (3%), whereas 37 (10%) cycles were
administered with reduction in the dose of both drugs. TEGAFOX
cycles were administered with only a reduced dose of UFT in 59
cycles (13%) and with only a reduced dose of L-OHP in 9 (2%),
whereas 16 (4%) cycles were administered with both drugs at
reduced doses. Most of these reductions consisted of 75% of the
initial dose.
Table 2 shows the adverse events reported during the treatment
with TEGAFIRI and TEGAFOX. The most common grade 3–4
treatment-related adverse events were neutropenia, which was
reported in 13% of cases with TEGAFIRI and in 1% in the
TEGAFOX group. Diarrhoea was prevalent in the TEGAFIRI arm
(16%) vs TEGAFOX (4%). No HFS was reported in the TEGAFIRI
group whereas grade 1–2 HFS was evident in 10% of the
TEGAFOX group. Abdominal pain, allergic reactions, infection,
liver toxicity and infection with fever were recorded as other
toxicity. However, the overall incidence of any type grade 3–4 side
effects was reported in 37–21% of TEGAFIRI and TEGAFOX
patients, respectively.
Sequential grade 3–4 toxicity (as defined in the Materials and
methods section) was recorded in four (5.9, 95% CL, from 1.6 to
14.4%) TEGAFIRI patients and three (4.1, 95% CL, from 0.9 to
11.5%) TEGAFOX patients.
Efficacy analysis
Eight patients in the TEGAFIRI group and one in the TEGAFOX
group interrupted therapy soon after the first cycle, owing to side
effects with no clinical benefit, and they were excluded. Thus, a
total of 60 TEGAFIRI cases and 72 TEGAFOX patients were
evaluable for efficacy analysis. Among these excluded cases, all
except two were more than 65 years old. Table 3 shows study
results on the best overall response rates. Six CR and 19 PR were
recorded in the TEGAFIRI arm, for an overall response rate of
41.7% (95% CL, from 29.1 to 55.1%). In the TEGAFOX arm, six CR
and 22 PR were recorded, corresponding to an overall response
rate of 38.9% (95% CL, from 27.6 to 51.1).
The median duration of response was 6 (range: 3–15) for
TEGAFIRI and 6 months (range: 3–23) for TEGAFOX group.
After a median time follow-up of 17 months (IQ range 12–23), a
median survival probability of 20 (IQ range 14–31) and 19 (IQ
range: 11–29) months was obtained in the TEGAFIRI and
TEGAFOX group, respectively. Median time to progression
reported was 8 months (IQ range 5–11) for TEGAFIRI and 8
months (IQ range: 5–14) for TEGAFOX patients. The overall
survival and time to progression are shown in Figures 2 and 3
respectively.
Table 1 Main basal characteristics
No. of pts (%)
TEGAFIRI
(No. 68 pts)
TEGAFOX
(No. 73 pts)
Age (years)
Median (range) 61 (36–74) 62 (23–73)
o 70 61 (89.7) 66 (90.4)
X70 7 (10.3) 7 (9.6)
M/F: 40 (58.8)/28 (41.1) 39 (53.4)/34 (46.5)
PS (ECOG)
0–1 58 (85.3)–10 (14.7) 66 (90.4)–5 (6.9)
2 — 2 (2.7)
Site of primary lesion
Colon dx 15 (22.1) 15 (20.6)
Colon sn 34 (50) 40 (54.7)
Rectum 19 (27.9) 18 (24.7)
No. of metastatic sites
1 31 (45.6) 43 (58.9)
2 26 (38.2) 15 (20.5)
X3 11 (16.2) 15 (20.5)
Adjuvant chemotherapy
Yes 13 (19.1) 14 (19.2)
Altered LDH value 27 (40) 15 (20)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; LDH, lactic
deydrogenase; pts, patients; PS.
Table 2 Frequency of patients reporting adverse events
% pts
TEGAFIRI (No. 68 pts) TEGAFOX (No. 73 pts)
Grade NCI CTC G1 G2 G3 G4 G1 G2 G3 G4
Diarrhoea 16.2 25.0 14.7 1.5 13.7 12.3 4.1 —
Nausea/emesis 29.4 26.5 11.8 — 19.2 31.5 2.7 —
Thrombocytop enia — — — 1.5 5.5 4.1 1.4 —
Neurotoxicity — — — — 30.1 13.7 4.1 1.4
Mucositis 1.5 — 1.5 — 4.1 4.1 — —
Asthenia 10.3 2.9 1.5 — 2.7 8.2 4.1 —
Alopecia 4.4 — 4.4 1.5 — — — —
HFS — — — — 5.5 4.1 — —
Leucopenia 1.5 4.4 8.8 1.5 4.1 2.7 1.4 —
Neutropenia 4.4 2.9 11.8 1.5 1.4 8.2 1.4 —
Anaemia 8.8 2.9 2.9 — 4.1 1.4 — —
Other 7.4 7.4 5.9 — 13.7 4.1 6.8 —
Any type 23.5 27.9 32.4 4.4 16.4 47.9 19.2 1.4
Abbreviations: HFS, hand–foot syndrome; NCI CTC¼National Cancer Institute Common Toxicity Criteria; pts, patients.
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sDISCUSSION
The introduction in clinical practice of combination therapies such
as FOLFIRI or FOLFOX has been an important development in
colorectal cancer patient treatment. But, at the same time, it also
creates some disadvantages such as the requirement of central
venous catheters (CVC), infusion pumps or repeated intravenous
administrations that are uncomfortable for the patients. Moreover,
positioning of CVC could be complicated by pneumothorax, local
infection, thrombosis and the frequent ambulatory visits that may
have a negative impact on quality of life.
To decrease the level of these complications, new oral 5-FU
prodrugs were introduced into the clinical practice. These agents
such as UFT and capecitabine have demonstrated a relevant
antitumour activity in preclinical trials and the pharmacokinetic
profile of these drugs is equivalent to infusion 5-FU (Ishikawa
et al, 1998). The role of oral fuoropyrimidines as a backbone of
combination regimens with L-OHP and CPT-11 is an open
question, although some phase II studies were carried out to
evaluate the safety profile and activity of the capecitabine-based
combinations (Bajetta et al, 2004; Reddy, 2005; Twelves et al,
2005). Whereas phase III trials comparing capecitabine-based and
infusion 5-FU-based combination regimens are ongoing, there is
no phase III trial evaluating the use of UFT/LV-based combina-
tions.
This randomised phase II study evaluates whether the introduc-
tion of UFT, modulated by LV, in combination schemes
determines a reduction of typical side effects with a satisfactory
efficacy with respect to infusion regimens FOLFIRI and FOLFOX.
The data obtained documents an incidence of grade 3–4
diarrhoea (16%) and grade 3–4 neutropenia (13%) in the
TEGAFIRI group and grade 3–4 neurotoxicity (6%), grade 3
diarrhoea (4%) and grade 3 neutropenia (1%) in the TEGAFOX
patients. Moreover, during the treatment, two sequentially
occurring grade 3–4 toxicities were reported in only 6% of
TEGAFIRI cases and 4% of TEGAFOX patients. It means that a
good safety profile has been obtained by a slight dose reduction
(25%) of the two combinations.
Regarding any type toxicity, the TEGAFIRI regimen (grade 3–4:
37%) shows an increase in incidence with respect to the TEGAFOX
regimen (grade 3–4: 21%). Twelve percent of TEGAFIRI patients
and 1% of the TEGAFOX group stopped treatment for side effects
soon after the first cycle; in the TEGAFIRI group, all cases were
more than 65 years old. This means that the TEGAFOX regimen
could be considered more suitable for older patients.
Other phase II trials have investigated the use of these two
combinations. The toxicity profile observed with TEGAFOX and
TEGAFIRI in the present study compares favourably with that
reported in other phase II trials (Feliu et al, 2004, (Mendez et al,
2005; Bennouna et al, 2006). In particular, the rate of TEGAFOX
grade 3–4 neurotoxicity was around 14–15% in Bennouna and
Feliu studies as compared with 6% in our study. This probably
correlated with the maximum number of administered cycles
according to the study design reported in our study. Regarding
TEGAFIRI, the toxicity rates of neutropenia and diarrhoea were
comparable with those reported by Mendez.
However, these toxicity profiles correspond to those reported
combining capecitabine and CPT11 or L-OHP with the exception
of the greater rate of HFS that is reported in 20% of patients
treated with capecitabine (Bajetta et al, 2004; Reddy, 2005; Twelves
et al, 2005). This side effect has not been reported frequently with
UFT.
The results we achieved with the employment of UFT modulated
with LV, when combined to CPT11 or L-OHP show an efficacy in
terms of response rate, time to progression and overall survival,
which was at least comparable to respective infusion regimens.
Moreover the efficacy, with overall response rates of 42% (in
TEGAFIRI) and 39% (in TEGAFOX), a median survival rate of 20
and 19 months in the TEGAFIRI and TEGAFOX group,
respectively, does not differ significantly from those reported in
different phase II studies with capecitabine combintions (31–50%)
(Bajetta et al, 2004; Reddy, 2005; Twelves et al, 2005).
Although we are waiting for the results of comparative phase III
studies with the employment of capecitabine, the UFT/LV
Table 3 Efficacy analysis
Best overall response
TEGAFIRI No.
60 pts (%)
TEGAFOX No.
72 pts (%)
Complete response 6 (10.0) 6 (8.3)
Partial response 19 (31.7) 22 (30.6)
Stable disease 23 (38.3) 25 (34.7)
Treatment failure 12 (20.0) 19 (26.4)
Objective response 25 (41.7)
(95% CL, 29.1–55.1%)
28 (38.9)
(95% CL, 27.6–51.%1)
Abbreviation: CL¼confidence limit.
Time (months)
18 12 6 0
P
r
o
b
a
b
i
l
i
t
y
0.0
0.2
0.4
0.6
0.8
1.0
TEGAFIRI
TEGAFOX
TEGAFIRI 68 61 46 22 
TEGAFOX 73 67 39 20
No. of patients at risk
Figure 2 Overall survival by treatment.
Time (months)
18  12 6 0
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r
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y
0.0
0.2
0.4
0.6
0.8
1.0
TEGAFIRI
TEGAFOX
TEGAFIRI 68  50 11 3
TEGAFOX 73 51 18 6
No. of patients at risk
Figure 3 Time to progression by treatment in analysed patients.
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scombinations studied can be considered a valid therapeutic option
in first-line therapy. It may be warranted to evaluate these
combinations with biological therapies such as bevacizumab or
cetuximab.
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